**Participant Flow**

**Baseline Characteristics**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|   | **IVR** | **Internet** | **Missing** | **Total** |
|   | **N** | **%** | **n** | **%** | **n** | **%** | **n** | **%** |
| **Age (years): mean (SD)** | 69 (10) | 60 (14) | 66 (9) | 62 (13) |
| **Gender** |   |   |   |   |   |   |   |   |
| Male | 23 | 53% | 90 | 48% | 6 | 60% | 128 | 51% |
| Female | 20 | 47% | 97 | 52% | 4 | 40% | 121 | 49% |
| **Study group** |   |   |   |   |   |   |   |   |
| Chemotherapy | 6 | 14% | 37 | 19% | 0 | 0% | 43 | 17% |
| Targeted agents | 5 | 12% | 40 | 20% | 1 | 10% | 46 | 18% |
| Hormone therapy | 13 | 30% | 26 | 13% | 4 | 40% | 43 | 17% |
| Radiotherapy | 8 | 19% | 34 | 17% | 1 | 10% | 43 | 17% |
| Surgery | 4 | 9% | 36 | 18% | 2 | 20% | 42 | 17% |
| ECOG | 7 | 16% | 23 | 12% | 2 | 20% | 32 | 13% |
| **Disease group** |   |   |   |   |   |   |   |   |
| Breast | 8 | 19% | 45 | 23% | 4 | 40% | 57 | 23% |
| Colorectal | 3 | 7% | 31 | 16% | 0 | 0% | 34 | 14% |
| Prostate | 12 | 28% | 19 | 10% | 2 | 20% | 33 | 13% |
| Leukaemia | 2 | 5% | 13 | 7% | 0 | 0% | 15 | 6% |
| Myeloma | 3 | 7% | 10 | 5% | 0 | 0% | 13 | 5% |
| Rectal/anal | 1 | 2% | 12 | 6% | 0 | 0% | 13 | 5% |
| Lung | 5 | 12% | 6 | 3% | 1 | 10% | 12 | 5% |
| Renal | 1 | 2% | 11 | 6% | 0 | 0% | 12 | 5% |
| Head & neck | 1 | 2% | 10 | 5% | 0 | 0% | 11 | 4% |
| Liver resections | 0 | 0% | 8 | 4% | 2 | 20% | 10 | 4% |
| Ovarian | 3 | 7% | 6 | 3% | 0 | 0% | 9 | 4% |
| Lymphoma | 0 | 0% | 8 | 4% | 1 | 10% | 9 | 4% |
| Bladder | 1 | 2% | 5 | 3% | 0 | 0% | 6 | 2% |
| Pancreas | 0 | 0% | 6 | 3% | 0 | 0% | 6 | 2% |
| Gastric | 1 | 2% | 5 | 3% | 0 | 0% | 6 | 2% |
| Oesophageal | 2 | 5% | 1 | 1% | 0 | 0% | 3 | 1% |

**Outcome measures**

Primary outcome measures

*Number of patients potentially eligible, number recruited and reasons for non-recruitment*

Recruitment began on 18th August 2014 (Leeds) and finished on 7th October 2015.

Number of patients potentially eligible = 888

Number of patients recruited = 249

Reasons for non-recruitment:

* 271 declined
* 364 ineligible
* 4 died before consent or decline

Secondary outcome measures

*Number of and timing of participant withdrawals from follow-up data collection and reasons for withdrawal*

Overall there were 13 withdrawals

**Number and timing of withdrawals**

|  |  |
| --- | --- |
|  |  |
| **Week** | **N** |
| 0 | 5 |
| 1 | 2 |
| 2 | 2 |
| 3 | 1 |
| 4 | 2 |
| 10 | 1 |

Reasons for withdrawals

|  |  |
| --- | --- |
|  | **N** |
|  |
| Taking too much time | 2 |
| Computer problems | 2 |
| Too ill | 2 |
| Phone problems | 1 |
| Other | 10 |

A large proportion of the reasons selected were “other” and further details were given as: “Can't concentrate”, “Too much on”, “Tired”, “Annoying IVR voice”, Felt it was a waste of time”, “Not relevant any longer”, “Difficulty coping”, “Didn't like the questions”, “Burden”, “Couldn't hear voice on IVR”, “Treatment stopped” and “Too much on mind”.

*Proportion of expected weekly AE reports completed*

|  |  |
| --- | --- |
|  | **Overall** |
|  |
| **Week** | **A** | **E** | **C** |
| 0 | 232 | 249 | 93.2 |
| 1 | 193 | 242 | 79.8 |
| 2 | 189 | 240 | 78.8 |
| 3 | 183 | 239 | 76.6 |
| 4 | 172 | 237 | 72.6 |
| 5 | 176 | 236 | 74.6 |
| 6 | 179 | 236 | 75.8 |
| 7 | 174 | 235 | 74 |
| 8 | 157 | 235 | 66.8 |
| 9 | 166 | 234 | 70.9 |
| 10 | 166 | 231 | 71.9 |
| 11 | 159 | 230 | 69.1 |
| 12 | 155 | 230 | 67.4 |

**Adverse events**

There were no adverse events associated with this trial.